XGN

Exagen Inc.

NasdaqAdd to watchlist

Healthcare · Diagnostics & Research

$7.34

−$0.05−0.68%

Delayed · 2026-08-31T20:00:00.000Z · marketstack

5 open-market sales on file ($628K), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$7.34

−$0.31−4.05%over 1M

Session

Day range86% of range

$7.04$7.39

Fundamentals

Visualize fundamentals and more

Market cap: 177.37M
P/E ratio: -

Revenue grew +19.65% in FY2025, +10.78% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 62
dropped: 53
re-drafted: 58

Out of 298 passages in this year’s Item 1A.

New this year

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report, including our financial statements and related …

114 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

Reimbursement
Litigation
FDA approval
Debt covenants
Data privacy
Dilution
Inflation
Tariffs

And 14 more.

Reimbursement
We also expect to continue to devote substantial resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. Over the next several years, we expect to continue to devote substantially all of our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Sep 1 Black Jeffrey G. sold 20,614 shares Insider trading Form 4 Chief Financial Officer, about $149k
Aug 4 Results announcement Company filing 8-K
Aug 4 Quarterly report Company filing 10-Q

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Aug 31, 2026 · the last close

Exagen Inc. investor relations

What XGN has filed with the SEC. This is not Exagen Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Exagen Inc.

Also filed under Diagnostics & Research, ranked by how closely they sit beside XGN.

TMOThermo Fisher Scientific Inc.compare with XGN
ILMNILLUMINA, Inc.compare with XGN
DHRDanaher Corp.

TWSTTwist Bioscience Corpcompare with XGN

AAgilent TECHNOLOGIES, Inc.compare with XGN

Ask about Exagen Inc.

The assistant answers from what XGN has actually filed: 8 annual reports filed with the SEC, 10 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from XGN's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Exagen Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Exagen Inc.

Be told the moment a XGN insider trades
Put Exagen Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Exagen Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Exagen Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Sep 1 Black Jeffrey G. sold 20,614 shares Insider trading Form 4 Chief Financial Officer, about $149k
Aug 4 Results announcement Company filing 8-K
Aug 4 Quarterly report Company filing 10-Q

15 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

Reimbursement
Litigation
FDA approval
Debt covenants
Data privacy
Dilution
Inflation
Tariffs

And 14 more.

Reimbursement
We also expect to continue to devote substantial resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. Over the next several years, we expect to continue to devote substantially all of our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 62
dropped: 53
re-drafted: 58

Out of 298 passages in this year’s Item 1A.

New this year

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report, including our financial statements and related …

114 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add